Ondansetron STADA
Antiemetic medication for chemotherapy, radiotherapy and post-operative nausea
Ondansetron STADA is a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It is one of the most widely prescribed antiemetic medications worldwide and is included on the WHO Model List of Essential Medicines. This guide covers dosage, side effects, drug interactions, and important safety information.
Quick Facts
Key Takeaways
- Ondansetron STADA prevents nausea and vomiting from chemotherapy, radiotherapy, and surgery by blocking serotonin 5-HT3 receptors.
- The standard adult dose for chemotherapy-induced nausea is 8 mg taken 1–2 hours before treatment, then 8 mg twelve hours later, continuing twice daily for up to 5 days.
- Do not take ondansetron with apomorphine (used for Parkinson's disease) — this combination is contraindicated.
- Avoid use during the first trimester of pregnancy due to a possible small increase in the risk of cleft lip/palate.
- The most common side effect is headache; serious but rare effects include heart rhythm disturbances and allergic reactions.
What Is Ondansetron STADA and What Is It Used For?
Ondansetron is one of the most important antiemetic medications available today and has been in clinical use since its first approval in the early 1990s. It works by selectively blocking serotonin type 3 (5-HT3) receptors, which are found both in the central nervous system (particularly in the chemoreceptor trigger zone of the brain) and in the peripheral nervous system along the vagal nerve endings in the gastrointestinal tract. By blocking these receptors, ondansetron prevents the cascade of signals that trigger nausea and the vomiting reflex.
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing side effects of cancer treatment. Without effective antiemetic prophylaxis, up to 90% of patients receiving highly emetogenic chemotherapy would experience significant nausea and vomiting. Ondansetron, either alone or as part of a multi-drug antiemetic regimen, has dramatically improved the quality of life for cancer patients undergoing treatment. The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) both recommend 5-HT3 receptor antagonists as a cornerstone of antiemetic therapy.
Ondansetron STADA is specifically indicated for three clinical scenarios. First, it is used to prevent nausea and vomiting associated with cytotoxic chemotherapy in both children (from 6 months of age) and adults. Second, it is approved for preventing nausea and vomiting caused by radiotherapy in adults. Third, it is used to prevent post-operative nausea and vomiting (PONV) in adults, a condition that affects approximately 30% of surgical patients and up to 80% of patients with certain risk factors.
Ondansetron STADA is a generic formulation manufactured by STADA Arzneimittel AG. Generic medicines contain the same active ingredient in the same dose as the original brand-name product and must demonstrate bioequivalence through rigorous regulatory testing. Other brands containing ondansetron include Ondansetron Accordpharma. The World Health Organization (WHO) includes ondansetron on its Model List of Essential Medicines, recognizing its critical importance in global healthcare.
What Should You Know Before Taking Ondansetron STADA?
Contraindications
There are two absolute contraindications to taking Ondansetron STADA. First, you must not take this medicine if you are also taking apomorphine, a medication used for treating Parkinson's disease. The combination of ondansetron and apomorphine can cause a dangerous drop in blood pressure and loss of consciousness. This interaction has been well-documented in clinical studies and is considered a strict contraindication by all major regulatory authorities including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Second, you should not take Ondansetron STADA if you have a known allergy or hypersensitivity to ondansetron or any of the other ingredients in the formulation. Cross-sensitivity may also occur with other 5-HT3 receptor antagonists such as granisetron or palonosetron. If you have previously experienced an allergic reaction to any medication in this drug class, inform your healthcare provider before starting ondansetron.
Never take Ondansetron STADA together with apomorphine. This combination can cause severe hypotension (dangerously low blood pressure) and loss of consciousness.
Warnings and Precautions
Before starting Ondansetron STADA, tell your doctor or pharmacist if any of the following conditions apply to you:
- Heart problems: If you have ever had heart failure causing shortness of breath and swollen ankles, or any form of irregular heartbeat (arrhythmia). Ondansetron can prolong the QT interval on an electrocardiogram (ECG), which in rare cases may lead to potentially dangerous heart rhythm disturbances including Torsades de Pointes.
- Liver disease: If you have moderate to severe liver problems, your body may metabolize ondansetron more slowly, leading to higher blood levels of the drug. Your doctor may need to reduce your dose. The total daily dose should not exceed 8 mg in patients with severe hepatic impairment.
- Bowel obstruction: If you have a blockage or obstruction in the bowel (intestines). Ondansetron slows the transit time through the large intestine, which could worsen an existing obstruction. Your doctor should be informed about any gastrointestinal conditions before prescribing ondansetron.
- Electrolyte imbalances: If you have problems with the levels of potassium, sodium, or magnesium in your blood. Low levels of these electrolytes (hypokalemia, hyponatremia, or hypomagnesemia) can increase the risk of QT prolongation and cardiac arrhythmias. Electrolyte disturbances are common in patients undergoing chemotherapy and should be corrected before starting ondansetron.
- Adenotonsillectomy: Ondansetron may mask the signs of progressive ileus and gastric distention after abdominal surgery. Monitor for these signs especially in the post-operative period.
Pregnancy and Breastfeeding
Ondansetron STADA should not be used during the first three months of pregnancy (first trimester). Epidemiological studies have suggested that ondansetron may slightly increase the risk of the baby being born with a cleft lip and/or cleft palate (orofacial clefts). While the absolute risk remains small, this is a serious consideration, and the EMA has issued specific guidance on this matter. If you are already pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking this medication. Women of childbearing age may be advised to use effective contraception while taking ondansetron.
Breastfeeding is not recommended while taking Ondansetron STADA. Studies have shown that small amounts of ondansetron are excreted in breast milk, and the potential effects on a nursing infant have not been fully established. Your healthcare provider can advise you on the safest approach, which may include expressing and discarding breast milk during the treatment period, or using an alternative antiemetic that is considered compatible with breastfeeding.
Driving and Operating Machinery
Ondansetron is generally not expected to impair your ability to drive or operate machinery. However, some people may experience dizziness, drowsiness, or visual disturbances as side effects. If you notice any of these symptoms, avoid driving or operating heavy machinery until you feel well. You are responsible for assessing your own fitness to drive, and the effects of medication are one factor to consider in this assessment.
Ondansetron STADA tablets contain lactose monohydrate as an inactive ingredient. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
How Does Ondansetron STADA Interact with Other Drugs?
Drug interactions are an important consideration when taking Ondansetron STADA. Because many patients receiving this medication are being treated for cancer or are in the post-operative period, they often take multiple medications simultaneously. Always inform your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter medicines and herbal supplements.
Major Interactions
| Drug / Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Apomorphine | Severe hypotension, loss of consciousness | CONTRAINDICATED — never use together |
| SSRIs (fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) | Increased risk of serotonin syndrome | Use with caution; monitor for symptoms |
| SNRIs (venlafaxine, duloxetine) | Increased risk of serotonin syndrome | Use with caution; monitor for symptoms |
| QT-prolonging drugs (haloperidol, methadone, antiarrhythmics) | Additive QT prolongation; risk of Torsades de Pointes | ECG monitoring recommended |
| Tramadol | Reduced analgesic effect of tramadol | Alternative pain relief may be needed |
Serotonin syndrome is a potentially serious condition that can occur when ondansetron is combined with serotonergic drugs such as SSRIs or SNRIs. Symptoms include agitation, confusion, rapid heart rate, elevated blood pressure, muscle rigidity, tremor, and in severe cases, high fever and seizures. If you experience any of these symptoms, seek medical attention immediately. The risk is particularly relevant because many cancer patients and surgical patients also take antidepressant medications.
Pharmacokinetic Interactions
| Drug | Mechanism | Effect on Ondansetron |
|---|---|---|
| Carbamazepine | CYP3A4 enzyme inducer | Reduced ondansetron blood levels; may decrease effectiveness |
| Phenytoin | CYP3A4 enzyme inducer | Reduced ondansetron blood levels; may decrease effectiveness |
| Rifampicin | Potent CYP3A4 enzyme inducer | Significantly reduced ondansetron blood levels |
| Erythromycin | CYP3A4 enzyme inhibitor | Potentially increased ondansetron blood levels |
| Ketoconazole | CYP3A4 enzyme inhibitor | Potentially increased ondansetron blood levels |
Ondansetron is primarily metabolized in the liver by the cytochrome P450 enzyme system, particularly CYP3A4, with additional contributions from CYP1A2 and CYP2D6. Drugs that induce these enzymes, such as carbamazepine, phenytoin, and rifampicin, can accelerate the breakdown of ondansetron, potentially reducing its antiemetic effectiveness. In patients taking strong enzyme inducers, healthcare providers may need to consider dose adjustments or alternative antiemetic strategies.
Conversely, drugs that inhibit CYP3A4, such as the antibiotic erythromycin and the antifungal ketoconazole, may slow the metabolism of ondansetron, leading to higher blood levels. While clinically significant toxicity from this interaction is uncommon, patients with additional risk factors for QT prolongation should be monitored more closely.
Additionally, certain cancer chemotherapy agents, particularly anthracyclines (such as doxorubicin) and trastuzumab, can themselves affect cardiac function. When these drugs are combined with ondansetron, careful cardiac monitoring is advisable, particularly in patients with pre-existing heart conditions. Beta-blockers, used for various cardiovascular conditions, anxiety, or migraine prevention, may also interact with ondansetron, and your doctor should be aware if you are taking any of these medications.
What Is the Correct Dosage of Ondansetron STADA?
Always take Ondansetron STADA exactly as your doctor has told you. The tablets should be swallowed whole with water. The dose prescribed depends on the type of treatment you are receiving. If you are unsure about anything, consult your doctor or pharmacist.
Adults — Chemotherapy and Radiotherapy
Day of Chemotherapy or Radiotherapy
The usual dose is 8 mg taken 1–2 hours before your chemotherapy or radiotherapy session, followed by an additional 8 mg twelve hours after the initial dose.
Following Days (Up to 5 Days)
The usual dose is 8 mg twice daily (morning and evening). This continuation therapy can be given for up to 5 days to prevent delayed nausea and vomiting, which commonly occurs 24–120 hours after chemotherapy.
For highly emetogenic chemotherapy regimens (such as cisplatin-based protocols), ondansetron is typically used as part of a multi-drug antiemetic combination. International guidelines from ESMO, ASCO, and MASCC recommend combining a 5-HT3 antagonist with a corticosteroid (such as dexamethasone) and, for the highest-risk regimens, an NK1 receptor antagonist (such as aprepitant). Your oncologist will determine the most appropriate antiemetic regimen for your specific chemotherapy protocol.
Adults — Post-Operative Nausea and Vomiting (PONV)
Pre-Operative Dose
The usual dose is 16 mg taken before the operation. This should be taken approximately 1 hour before the induction of anaesthesia.
Children and Adolescents
For chemotherapy-induced nausea and vomiting in children aged 6 months and older, the doctor will calculate the appropriate dose based on the child's body surface area (BSA) or body weight. The usual oral dose for children is up to 4 mg twice daily for up to 5 days. In younger children or when oral administration is not possible, ondansetron is typically given as an intravenous injection, and the dose is calculated according to body weight (typically 0.15 mg/kg).
For post-operative nausea and vomiting in children aged 1 month and older, ondansetron is recommended to be given as an intravenous injection rather than oral tablets. The injectable formulation allows more precise dosing and faster onset of action in the peri-operative setting.
| Indication | Patient Group | Dose | Duration |
|---|---|---|---|
| Chemotherapy / Radiotherapy | Adults | 8 mg before treatment + 8 mg after 12 h, then 8 mg twice daily | Up to 5 days |
| Chemotherapy | Children (≥6 months) | Up to 4 mg twice daily (dose by BSA/weight) | Up to 5 days |
| Post-operative (PONV) | Adults | 16 mg before surgery | Single dose |
| Post-operative (PONV) | Children (≥1 month) | IV injection recommended | As directed |
| Any indication | Moderate/severe liver impairment | Max 8 mg per day | As directed |
Patients with Liver Problems
In patients with moderate or severe liver impairment (hepatic dysfunction), the metabolism of ondansetron is significantly reduced, leading to higher and more prolonged drug levels in the blood. For this reason, the total daily dose should not exceed 8 mg in these patients. Your doctor will assess your liver function through blood tests and adjust the dose accordingly. This dose limitation applies regardless of the indication for which ondansetron is being prescribed.
Missed Dose
If you forget to take a dose and feel nauseous or are vomiting, take Ondansetron STADA as soon as you remember, then take the next dose at the usual time. If you forget a dose and do not feel nauseous, simply take the next dose at the usual time. Do not take a double dose to make up for a forgotten one.
Overdose
If you or someone else has taken too much Ondansetron STADA, contact your doctor, hospital, or poison control center immediately. Take the medicine packaging with you so the healthcare professionals know what has been taken. Clinical experience with ondansetron overdose is limited, but reported symptoms include visual disturbances, severe constipation, hypotension (low blood pressure), and vasovagal episodes. There is no specific antidote for ondansetron; treatment is supportive and symptomatic.
Ondansetron begins to work within 1–2 hours after taking an oral dose. If you vomit within 1 hour of taking a dose, take the same dose again. If vomiting continues, contact your doctor or pharmacist.
What Are the Side Effects of Ondansetron STADA?
Like all medicines, Ondansetron STADA can cause side effects, although not everybody gets them. Most side effects are mild and temporary, resolving on their own as your body adjusts to the medication. However, some side effects can be serious and require immediate medical attention. Below is a comprehensive overview of known side effects organized by frequency, from most common to rarest.
If you experience any of the following signs of a severe allergic reaction, stop taking the tablets immediately and seek emergency medical help: sudden wheezing, chest pain or tightness, swelling of eyelids, face, lips, mouth or tongue, skin rash with red spots or lumps (hives), or collapse.
Very Common
May affect more than 1 in 10 people
- Headache
Common
May affect up to 1 in 10 people
- Sensation of warmth or flushing
- Constipation
- Changes in liver function test values (especially when taken with cisplatin; otherwise less common)
Uncommon
May affect up to 1 in 100 people
- Hiccups
- Low blood pressure (hypotension), possibly causing faintness or dizziness
- Irregular heartbeat (arrhythmia)
- Chest pain
- Seizures (convulsions)
- Unusual involuntary movements or tremor (extrapyramidal reactions)
Rare
May affect up to 1 in 1,000 people
- Dizziness or feeling faint
- Blurred vision
- Heart rhythm disturbances (which may sometimes cause sudden loss of consciousness)
- Severe allergic reactions (anaphylaxis) — see warning above
Very Rare
May affect up to 1 in 10,000 people
- Poor vision or temporary loss of vision (vision usually returns within 20 minutes)
Frequency Not Known
Cannot be estimated from available data
- Myocardial ischaemia (reduced blood supply to the heart muscle), with signs including sudden chest pain or pressure
The cardiac effects of ondansetron, particularly QT interval prolongation, have received significant attention from regulatory agencies worldwide. The EMA and FDA have both issued guidance noting that ondansetron should be used with caution in patients with pre-existing cardiac conduction disorders, electrolyte abnormalities, or who are taking other medications that prolong the QT interval. The risk of serious cardiac arrhythmias is greatest in patients with multiple risk factors, and the intravenous formulation (administered too rapidly) carries a higher risk than the oral formulation.
Transient visual disturbances, including temporary blindness, have been reported predominantly with intravenous administration. These episodes are typically self-limiting and resolve within 20 minutes, although isolated cases have taken longer. The exact mechanism is not fully understood but is thought to relate to 5-HT3 receptor blockade in the visual cortex. Patients should be reassured that vision recovery is expected.
If you experience any side effects, including any not listed in this guide, talk to your doctor, pharmacist, or nurse. You can also report suspected side effects directly to your national pharmacovigilance authority (e.g., the MHRA Yellow Card Scheme in the UK, FDA MedWatch in the USA, or the EMA EudraVigilance system in the EU). Reporting side effects helps ensure the continued monitoring of the benefit-risk balance of this medicine.
How Should You Store Ondansetron STADA?
Ondansetron STADA tablets do not require any special storage conditions. They should be stored at room temperature, away from excessive heat, moisture, and direct sunlight. There is no need to refrigerate the tablets. Keep the tablets in their original blister packaging until you are ready to take them, as this helps protect them from moisture and light.
As with all medicines, keep Ondansetron STADA out of the sight and reach of children. Store it in a safe location, preferably in a locked medicine cabinet or high shelf. Accidental ingestion by children can be harmful and should be treated as a medical emergency.
Do not use Ondansetron STADA after the expiry date printed on the carton and blister pack. The expiry date refers to the last day of the stated month. Once the expiry date has passed, return any unused tablets to your pharmacy for proper disposal.
Do not dispose of medicines by flushing them down the toilet or putting them in household waste. Ask your pharmacist about how to properly dispose of medicines you no longer use. These measures help protect the environment and prevent accidental exposure. Many countries have take-back programs or designated collection points for unused medicines.
What Does Ondansetron STADA Contain?
Active Ingredient
Each film-coated tablet contains ondansetron as the hydrochloride dihydrate salt. This is the pharmacologically active compound responsible for the antiemetic effect. The tablets are available in two strengths: 4 mg and 8 mg of ondansetron (measured as the free base).
Inactive Ingredients (Excipients)
The inactive ingredients are substances that are pharmacologically inactive but necessary for the manufacturing, stability, and administration of the tablet. They include:
- Tablet core: Microcrystalline cellulose (bulking agent), lactose monohydrate (filler), pregelatinized maize starch (disintegrant and binder), magnesium stearate (lubricant)
- Film coating: Hypromellose (film-forming agent), hydroxypropylcellulose (coating material), propylene glycol (plasticizer), sorbitan oleate (emulsifier), sorbic acid (preservative), vanillin (flavouring agent), titanium dioxide E171 (white colouring), quinoline yellow E104 (yellow colouring)
Packaging
Ondansetron STADA tablets are supplied in PVC/aluminium blister packs contained within an outer carton. Available pack sizes include 6, 9, 10, 15, 30, 50, or 100 tablets for both the 4 mg and 8 mg strengths. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Ondansetron STADA
Ondansetron STADA is used to prevent nausea and vomiting caused by chemotherapy (in children and adults), radiotherapy for cancer (adults only), and surgery (adults only). It belongs to the 5-HT3 receptor antagonist class and works by blocking serotonin receptors that trigger the vomiting reflex in the brain and gastrointestinal tract.
For chemotherapy-related nausea, the usual adult dose is 8 mg taken 1–2 hours before treatment, followed by another 8 mg twelve hours later, then 8 mg twice daily for up to 5 days. For post-operative nausea prevention, the dose is 16 mg taken before surgery. Swallow the tablets whole with water. Always follow your doctor's specific instructions.
Ondansetron should not be used during the first trimester of pregnancy (first 12 weeks) as it may slightly increase the risk of cleft lip and/or cleft palate in the baby. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medication. Your doctor can discuss the benefits and risks with you and suggest alternatives if needed.
The most common side effect is headache, affecting more than 1 in 10 people. Common side effects (up to 1 in 10) include sensation of warmth or flushing, constipation, and changes in liver function tests (particularly when taken with cisplatin). Uncommon side effects include hiccups, low blood pressure, and irregular heartbeat. Most side effects are mild and temporary.
Yes, Ondansetron STADA can interact with SSRIs (such as fluoxetine, paroxetine, sertraline) and SNRIs (such as venlafaxine, duloxetine). These combinations may increase the risk of serotonin syndrome, a potentially serious condition with symptoms including agitation, confusion, rapid heartbeat, and muscle rigidity. Always inform your doctor about all medications you are taking, especially antidepressants.
Ondansetron STADA is a generic version containing the same active ingredient (ondansetron) as brand-name Zofran, originally developed by GlaxoSmithKline. Both products have equivalent efficacy and safety profiles. Generic medicines must meet the same strict regulatory quality, safety, and bioequivalence standards as the original brand-name products before they can be approved for sale.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization. Available at: who.int/publications
- Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016;27(suppl 5):v119–v133. doi:10.1093/annonc/mdw270
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. 2020;38(24):2782–2797. doi:10.1200/JCO.20.01296
- European Medicines Agency (EMA). Assessment report on ondansetron and risk of orofacial clefts. EMA/PRAC/783018/2019. 2020.
- Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Annals of Emergency Medicine. 2014;64(1):19–25. doi:10.1016/j.annemergmed.2013.10.026
- Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 2020;131(2):411–448. doi:10.1213/ANE.0000000000004833
- British National Formulary (BNF). Ondansetron. National Institute for Health and Care Excellence (NICE). Updated 2024. Available at: bnf.nice.org.uk
- Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine. 2016;374(14):1356–1367. doi:10.1056/NEJMra1515442
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in clinical pharmacology, oncology, and internal medicine. Our team follows international medical guidelines from the WHO, ESMO, ASCO, and MASCC to ensure the highest level of accuracy and clinical relevance.
All content undergoes a rigorous multi-step review process: initial medical writing by subject-matter experts, peer review by independent physicians, fact-checking against current clinical guidelines, and regular updates to reflect new evidence and regulatory changes. We adhere to the GRADE evidence framework and declare no conflicts of interest. iMedic receives no commercial funding from pharmaceutical companies.
For questions about this article or our editorial process, please visit our Medical Team page or contact us.